Table 2.
Cytokine production in liver tissues of wild type and COX-2 transgenic mice with or without LPS/D-GalN injection
| Treatment | Vehicle |
LPS/D-GalN |
||
|---|---|---|---|---|
| wild type | COX-2 Tg | wild type | COX-2 Tg | |
| FGF | 21.81±5.62 | 18.13±3.22 | 20.91±1.98 | 25.68±5.08 |
| IFN-γ | ND | ND | ND | ND |
| IL-12(p40/p70) | 0.29±0.02 | 0.61±0.10 | 1.59±0.51* | 0.68±0.05 |
| TNF-α | ND | ND | 0.20±0.05** | 0.25±0.15 |
| VEGF | 2.43±0.22 | 2.60±0.70 | 1.12±0.14 | 1.00±0.06 |
| IL-2 | 0.88±0.11 | 1.00±0.15 | 1.21±0.20 | 0.84±0.09 |
| IL-4 | ND | ND | ND | ND |
| IL-5 | ND | ND | 0.99±0.08 | 1.05±0.46 |
| IL-10 | 3.78±1.25 | 3.50±0.43 | 9.48±2.04* | 3.81±0.35 |
| IP-10 | 2.68±0.40 | 3.89±1.09 | 386.00±129.13** | 139.27±6.96 |
| KC | 1.12±0.12 | 1.38±0.14 | 3.57±0.42** | 1.41±0.02 |
| MCP-1 | 0.19±0.02 | 0.21±0.02 | 2.77±0.50** | 1.22±0.13 |
| MIG | 0.32±0.04 | 0.39±0.07 | 4.44±0.12** | 5.45±1.24 |
| MIP-1α | 0.35±0.05 | 0.52±0.10 | 8.96±0.93** | 4.04±0.06 |
| IL-1β | 0.50±0.07 | 0.60±0.10 | 6.71±0.99** | 4.07±1.28 |
| IL-6 | 3.13±0.43 | 3.50±0.54 | 3.10±0.57 | 2.35±0.49 |
| GM-CSF | ND | ND | ND | ND |
| IL-1α | 0.47±0.13 | 0.52±0.10 | 51.27±14.81** | 12.22±0.08 |
| IL-13 | 1.32±0.19 | 1.70±0.31 | 1.97±0.49 | 1.54±0.34 |
| IL-17 | 0.30±0.05 | 0.41±0.11 | 0.48±0.16 | 0.29±0.08 |
Values are in pg/mg wet weight of liver tissue and as expressed as mean ± SD from 3−5 experiments (*p <0.05, **p<0.01; compared to wild type animals treated with vehicle alone). ND, undetectable (below detectable limit of the assay). FGF, fibroblast growth factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IL, interleukin; IFN-γ, interferon-γ; IP-10; interferon-inducible protein-10; KC, keratinocyte-derived chemokine (KC); MCP-1, monocyte chemoattractant protein-1; MIG, monokine induced by interferon-γ; MIP-1α, macrophage inflammatory protein-1α; TNF-1α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.